Interpace Biosciences, Inc.
IDXGD- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001054102
No open-market purchases or sales by Interpace Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesIDXG
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Interpace Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Interpace Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Burnell Thomas W. | CEO, President & Chairman | 1,455,927 | Aug 20, 2026 | 1 |
| Aggarwal Vijay | Director | – | Aug 20, 2026 | 1 |
| Rocca Fortunato R. | Director | – | Aug 20, 2026 | 1 |
| Keegan Joseph D | Director | – | Aug 20, 2026 | 1 |
| Sullivan Stephen J | Director | – | Aug 20, 2026 | 1 |
| McCarthy Christopher | CFO & COO | 323,800 | Aug 20, 2026 | 1 |
| 1315 Capital II, L.P. | 10% Owner | 9,405,941 | Feb 17, 2026 | 1 |
| Ampersand 2018 Limited Partnership | 10% Owner | 13,861,386 | Feb 4, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.